Study summary

Intravenous iron modestly reduced heart failure hospital stays or death

FAIR-HF2 trial (IV iron) · 1,105 people, randomized trial · Published June 2025, JAMA

141cardiovascular deaths or first heart failure hospitalizations with iron, vs 166 with placebo

What was tested

Ferric carboxymaltose, intravenous iron, against placebo in heart failure (ejection fraction 45% or less) with iron deficiency.

What they found

What it means

Iron testing and treatment remain reasonable; the size of benefit is modest.

JAMA, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.